CD19 and lymphoma: DT2219ARL, an immunotoxin composed of CD19 and CD22 scFv linked to diphtheria toxin, is the only FDC developed for hematologic malignancies, and has shown activity in phase 1/2 trials of r/r B-cell leukemia or lymphoma (NCT00889408, NCT02370160) [196].